Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JULIA VALDESPINA

Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner

NPI
1508510439
CMS profile
11361801
Location
WYOMING, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,609.64

85 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,534.89 83
Education $74.75 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JULIA VALDESPINA

NPI 1508510439 · CMS profile ID 11361801

Physician Assistants & Advanced Practice Nursing Providers / Nurse Practitioner

WYOMING, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508510439?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JULIA VALDESPINA, NPI 1508510439, CMS profile ID 11361801. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508510439?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JULIA VALDESPINA, NPI 1508510439, CMS profile ID 11361801. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508510439?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JULIA VALDESPINA, NPI 1508510439, CMS profile ID 11361801, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1508510439?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

85 matching records · $1,609.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 85 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–85 of 85.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Organogenesis Inc. $21.1506/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145465325 CMS
Janssen Biotech, Inc. $13.7906/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078770385 CMS
Medtronic, Inc. $29.8005/30/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247013623 CMS
Medtronic, Inc. $18.9905/30/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247013625 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $4.5305/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153461838 CMS
Phathom Pharmaceuticals, Inc. $13.4605/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151212353 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.1905/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153563262 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.5805/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153729474 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $3.9505/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153604315 CMS
ABBVIE INC. $16.3605/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1108344055 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $3.0005/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153682931 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1.4005/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153704668 CMS
ABBVIE INC. $26.2504/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1108344051 CMS
ABBVIE INC. $14.7104/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1108344053 CMS
Janssen Biotech, Inc. $60.9904/23/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078770287 CMS
Merck Sharp & Dohme LLC $14.2404/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141769488 CMS
ABBVIE INC. $2.7304/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1108344049 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1.3704/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153409485 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.2304/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153610698 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.7404/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153661150 CMS
Fresenius Kabi USA, LLC $26.7604/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146950068 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $3.4904/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153755383 CMS
Takeda Pharmaceuticals U.S.A., Inc. $42.5504/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137837471 CMS
Intercept Pharmaceuticals, Inc. $14.7904/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113650243 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $5.8803/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153698975 CMS
Lilly USA, LLC $29.3603/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135720139 CMS
Janssen Biotech, Inc. $15.2403/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078770360 CMS
Intercept Pharmaceuticals, Inc. $20.1203/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113650241 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.9502/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153703781 CMS
ABBVIE INC. $17.8602/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1108344047 CMS
Regeneron Healthcare Solutions, Inc. $15.5202/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114384697 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.2901/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153633824 CMS
Celgene Corporation $14.7301/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101100254 CMS
Ardelyx, Inc. $25.2201/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146748895 CMS
Celgene Corporation $18.5001/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101100252 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $222.92 11
PY2023 $4,503.75 86
PY2024 $1,609.64 85
PY2025 $1,716.19 92

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,364.37 32

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient SANOFI US SERVICES INC. $67.50 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226146637
Recipient SANOFI US SERVICES INC. $67.50 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226146641
Recipient SANOFI US SERVICES INC. $34.04 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226146646
Recipient SANOFI US SERVICES INC. $34.04 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226146651
Recipient SANOFI US SERVICES INC. $67.50 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226146656
Recipient SANOFI US SERVICES INC. $67.50 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226146660
Recipient SANOFI US SERVICES INC. $146.34 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226146663
Recipient SANOFI US SERVICES INC. $146.33 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226146667
Recipient SANOFI US SERVICES INC. $34.04 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226146670
Recipient SANOFI US SERVICES INC. $34.04 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226146674
Recipient SANOFI US SERVICES INC. $145.62 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226146678
Recipient SANOFI US SERVICES INC. $145.62 07/18/2025 Covered Recipient Non-Physician Practitioner A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226146682
Recipient SANOFI US SERVICES INC. $67.50 07/17/2025 Covered Recipient Non-Physician Practitioner A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226146629
Recipient SANOFI US SERVICES INC. $67.50 07/17/2025 Covered Recipient Non-Physician Practitioner A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226146633
Recipient SANOFI US SERVICES INC. $67.50 07/17/2025 Covered Recipient Non-Physician Practitioner A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226146701
Recipient SANOFI US SERVICES INC. $67.50 07/17/2025 Covered Recipient Non-Physician Practitioner A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226146706
Recipient SANOFI US SERVICES INC. $62.50 07/16/2025 Covered Recipient Non-Physician Practitioner A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226146686
Recipient SANOFI US SERVICES INC. $62.50 07/16/2025 Covered Recipient Non-Physician Practitioner A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226146690
Recipient SANOFI US SERVICES INC. $229.68 07/14/2025 Covered Recipient Non-Physician Practitioner A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226146694
Recipient SANOFI US SERVICES INC. $229.67 07/14/2025 Covered Recipient Non-Physician Practitioner A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226146698
Recipient SANOFI US SERVICES INC. $155.21 03/06/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146621
Recipient SANOFI US SERVICES INC. $72.00 03/06/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146624
Recipient SANOFI US SERVICES INC. $323.11 02/08/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146577
Recipient SANOFI US SERVICES INC. $681.09 02/08/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146582
Recipient SANOFI US SERVICES INC. $641.84 02/08/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146586
Recipient SANOFI US SERVICES INC. $69.00 02/08/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146610
Recipient SANOFI US SERVICES INC. $69.00 02/08/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146615
Recipient SANOFI US SERVICES INC. $74.50 02/08/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146619
Recipient SANOFI US SERVICES INC. $69.00 02/07/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146595
Recipient SANOFI US SERVICES INC. $85.00 02/07/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146599
Recipient SANOFI US SERVICES INC. $102.00 02/07/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146603
Recipient SANOFI US SERVICES INC. $178.20 02/06/2025 Covered Recipient Non-Physician Practitioner A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226146592